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Cellular energy metabolism is one of the main process that is affected during the 
transition from normal to cancer cells. This was recognized several years ago by 
Warburg (1930) who observed that neoplastic cells produce high amounts of 
lactic acid even in the presence of oxygen (Warburg O, 1930). This metabolic 
behaviour, named aerobic glycolysis, was  attributed by Warburg to an 
impairment of cell respiration with a consequent enhancement of glycolysis to 
cope with the high energetic needs of neoplastic cells. 
Warburg also proposed that the impaired cell respiration was the prime cause of 
cancer. However, this theory was considered too simplistic, since it did not 
directly link the molecular mechanism of uncontrolled cell growth to the impaired 
respiration. Interest in the metabolic property of cancer continued up to the 1960s 
and began to decline concomitantly with the widespread application of newer 
molecular techniques (Gatenby RA and Gillies RJ, 2004). So, the view of cancer 
as a metabolic disease was gradually displaced with the view of cancer as a 
genetic disease. However, in recent years, interest has been renewed as it has 
become clear that many of the signalling pathways that are affected by genetic 
mutations have a profound effect on core metabolism, making this topic once 
again one of the most intense areas of research in cancer biology.  
To date it is well documented that  the metabolic reprogramming of cancer cells is 
the direct result of alterations in oncogenes and oncosuppressors (Levine AJ et al, 
2010; Buchakjian MR et al, 2010). For instance, c-myc is known to transactivate 
most of genes of glycolytic enzymes, including lactate dehydrogenase A (LDH-A) 
and the glucose transporter 1 (GLUT1), and to enhance both glucose uptake and 
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lactate production (Osthus RC et al, 2000; Shim H et al, 1997). It has been 
proposed that the hypoxic environment, where tumors develop, promotes the 
stabilization of hypoxia inducible factor 1 alpha (HIF1α) which in turn induces 
the expression of glycolytic enzymes (aldolase, phosphoglycerate kinase, 
phosphofructokinase, pyruvate kinase and LDH-A) and GLUT1 (Semenza GL et 
al, 1994; Elbert BL et al, 1995). As a further example, hyperactivation of Akt, 
which is one of the most frequently observed mutations in human cancers, was 
reported to contribute both to the increased proliferation of cancer cells and to 
their highly glycolytic phenotype (Robey RB and Hay N, 2009). 
The tumor suppressor protein p53 has also been involved in the glycolytic shift of 
cancer cells. On the one hand, overexpression of a dominant negative mutant p53 
can be found in some tumors and leads to the induction of hexokinase II (HK-II) 
and to an increased glucose uptake (Mathupala SP et al, 1997; Smith TA et al, 
2006).  On the other hand, loss-of-function of the tumor suppressor p53 promotes 
an enhanced glycolytic phenotype by the repression of TIGAR (TP53-induced 
glycolysis and apoptotic regulator) expression, which normally down-regulates 
fructose-2,6-bisphosphatase, thus decreasing the glycolytic rate. Likewise, loss-
of-function of p53 diminishes the expression of SCO-2, a gene required for the 
appropriate assembly of cytochrome c oxidase, and thus limits the activity of 
mitochondria in the cancer cells (Bensaad K et al, 2006). 
The glycolysis-based metabolism of cancer cells is further promoted by the 
expression of a spliced variant form of pyruvate kinase (PKM2), which is less 
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active and was found to cause reduced oxygen consumption and increase lactate 
production (Vander Heiden MG et al, 2010). 
 
 
 
  
 
 
 
 
 
 
Modified from Ortega AD et al, 2009 
Figure 1. Genetic alterations underlying the glycolytic phenotype of cancer cells. 
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Glycolysis and “aerobic glycolysis” 
 
The first biochemical reactions of glucose metabolism, which generate two 
residues of reduced NAD and of pyruvic acid from one molecule of sugar, are the 
same in normal and in neoplastic cells.  In normal cells, NADH is then re-
oxidized by the highly active respiratory chain and pyruvic acid, after 
decarboxylation to acetyl-CoA, enters the TCA cycle.  On the contrary, in 
neoplastic cells reduced NAD is re-oxidized by pyruvic acid, a reaction catalyzed 
by the enzyme lactate dehydrogenase (LDH) which converts pyruvic into lactic 
acid. The regeneration of NAD by LDH activity allows a sustained glucose 
consumption with a build up of lactate (aerobic glycolysis).  In aerobic glycolysis 
each molecule of glucose is metabolized to two residues of lactic acid, with a net 
gain of two ATP residues.  
 
 
 
 
 
 
 
 
Granchi C et al, 2012 
Figure 2. Glucose metabolism through the glycolytic flux. 
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Contrary to normal, non proliferating cells, which typically adopt a catabolic 
metabolism focused on maximizing energy yield through the complete demolition 
of glucose to CO2, cancer cells are characterized by an anabolic-type metabolism, 
aimed at biomass construction. As a result of increased glucose uptake and 
glycolysis, high levels of glycolytic intermediates are generated, which can be 
used to obtain the building blocks needed for macromolecular biosynthesis. 
Anabolic pathways branching from glycolysis are in fact responsible for 
producing some amino acids, as well as both lipid and nucleotide precursors 
(Christofk HR et al, 2008). 
It is worth noting that this anabolic-type metabolism is not exclusive of cancer 
cells, but can also be observed in normal tissues when a rapid cell division is 
required, such as during embryonic development, in wound healing or during the 
activation of immune responses. Contrary to what supposed in past years, 
proliferating normal cells and a large part of cancer cells use glycolysis mainly to 
generate new macromolecules, and still derive a significant fraction of their ATP 
from oxidative phosphorylation (Bellance N et al, 2009). Glycolytic ATP 
becomes a more important energetic resource when the hypoxic 
microenvironment hinders mitochondrial function, such as in the healing wound 
bed or in hypo-vascularized tumor regions. The increased lactate production 
operated by LDH also contributes to the development of extracellular acidosis, a 
factor which finally facilitates tumor invasion and metastasis (Neri D and Supuran 
CT, 2011), although it should be reiterated that lactic acid is not just a discharge 
product; instead it actively participates in angiogenesis, migration, immune and 
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radio-resistance (Sonveaux P et al, 2008). Moreover it is involved in energy 
production thanks to a particular cell-cell shuttle system, also known as the 
“lactate shuttle” (Draoui N and Feron O, 2011). Tumor cells usually can be 
classified into two categories: “normoxive/glycolytic”, which are closer to blood 
vessels, or “hypoxic/glycolytic”, which are further away from the vascular 
network; these two cell types establish a symbiotic cell-cell shuttling of lactate. In 
general, glucose is actively taken up through the transporter GLUT into less 
oxygenated cells, which use it in the glycolytic process to produce ATP. The final 
conversion of pyruvate to lactate is catalyzed by lactate dehydrogenase 5 (LDH-
5). The monocarboxylate transporter 4 (MCT4) then extrudes lactic acid from 
hypoxic cells into the extracellular milieu. Lactate then functions as a metabolic 
fuel in oxidative tumor cells, where it is taken up through the monocarboxylate 
transporter 1 (MCT1) and oxidized to pyruvate by LDH-1, thus entering the TCA 
cycle in mitochondria with production of energy and CO2.  
 
 
 
 
 
 
 
Porporato PE et al, 2011 
Figure 3. The lactate-shuttle system. 
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In some tumors, a symbiosis between lactate producing cells and lactate 
consuming cells was also observed. By studying the metabolic profile of 
neoplastic cells and associated fibroblasts obtained from breast cancer specimens, 
Pavlides et al. (Pavlides S et al, 2009) observed that cells from tumor stroma 
display metabolic features similar to those of wound-healing fibroblasts and 
secrete high levels of lactate and pyruvate originating from aerobic glycolysis. 
The Authors hypothesized that these energetic metabolites can be taken by 
epithelial cancer cells and used to fuel the TCA cycle, resulting in efficient energy 
production and in a consequent  proliferative advantage for cancer cells. This 
proposed metabolic relationship between cancer stromal and parenchymal cells 
has been termed “reverse Warburg effect”. 
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Inhibition of aerobic glycolysis as a possible strategy to hinder 
cancer cell proliferation 
 
The observation that cancer cells exhibit increased glycolysis and are more 
dependent on this pathway  to ATP  generation has led to the evaluation of 
glycolytic inhibitors as potential anticancer agents. One of the first studied 
inhibitors was 3-bromopyruvate, a compound which inhibits hexokinase  and has 
been shown to abolish ATP production and cause severe depletion of cellular 
ATP. 3-Bromopyruvate was shown to exhibit potent cytotoxic activity against 
cancer cells with mitochondrial respiratory defects and cells in hypoxic conditions 
(Pelicano H et al, 2006). 
Another glycolytic inhibitor is 2-deoxyglucose (2-DG) which is a glucose 
analogue and has long been known to act as a competitive inhibitor of glucose 
metabolism. 2-DG is phosphorylated by hexokinase to 2-DG-phosphate, but 
unlike glucose-6-phosphate, cannot be further metabolized by phosphohexokinase 
isomerase which converts glucose-6-phosphate to fructose-6-phosphate. In this 
manner, 2-DG causes ATP depletion, leading to blockage of cell cycle 
progression and cell death in vitro (Pelicano H et al, 2006). 
Several other glycolysis inhibitors have been shown to have promising anticancer 
activity in vitro and in vivo, and some of them have entered clinical trials; 
however, it should be recognized that there are potential obstacles in using 
glycolytic inhibitors for cancer treatment: in fact, glycolytic enzymes are also 
necessary to glucose metabolism of normal cells and their inhibition can cause 
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severe disorders produced by the impaired glucose utilization. It is known that 
certain normal tissues including brain, retina and testis use glucose as the main 
energy source. In this way, inhibition of glycolysis may be potentially toxic for 
these tissues. 
In the laboratory where I worked during my PhD project, studies were focused on 
lactate dehydrogenase (LDH), which converts pyruvate to lactate. LDH is the only 
enzyme whose inhibition should allow a blocking of aerobic glycolysis of tumor 
cells without damaging normal cells which in conditions of normal functional 
activity and sufficient oxygen supply do not need this enzyme. The LDH 
inhibition as an approach to anticancer was proposed several years ago (Fiume L, 
1960; Papacostantinou J and Colowick SP, 1961a; Papacostantinou J and 
Colowick SP, 1961b) and is currently under active investigation (Manerba M et 
al, 2012; Granchi C et al, 2010; Ward RA et al, 2012). Interest in LDH as an 
anticancer therapeutic target also comes from the observation that this enzyme 
(namely its –A isoform) becomes constantly up regulated during neoplastic 
change (Levine AJ  et al, 2010; DeBerardinis RJ et al, 2008; Buchakjian MR et al, 
2010; Dang CV and Gao P, 2009), offering the possibility of a therapeutic 
intervention aimed at correcting this altered activity. LDH-A is trascriptionally 
up-regulated by HIF-1, and it was found to be correlated with aggressive 
phenotypes and poor prognosis in several tumor types (Koukourakis MI  et al, 
2003; Kolev Y  et al , 2008). Early literature data indicated that up-regulation of 
LDH-A under c-myc control ensures efficient aerobic glycolysis in tumor cells, 
conferring growth advantage (Shim H et al, 1997), whereas this enzyme does not 
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seem to be as necessary for healthy cells under normal conditions, as they 
generally use the aerobic oxidation pathway. A definitive confirmation of the key 
role of LDH-A in tumor maintenance was obtained by inhibition of LDH-A 
expression by shRNA, which decreased the ability of tumors to proliferate under 
hypoxic conditions and stimulated mitochondrial respiration (Fantin VR et al, 
2006; Wang ZY et al, 2012). Moreover, increased expression of LDH-A plays an 
important role in resistance of human breast cancer cells against paclitaxel and 
trastuzumab: this observation was proven by genetically down-regulating LDH-A, 
which led to a significantly increased sensitivity of resistant cells to both 
anticancer agents (Zhou M et al 2010; Zhao Y et al, 2011). Furthermore, LDH-A 
knockdown by shRNA, in fumarate hydratase deficient cells which rely on 
glycolytic metabolism,  results in a significant decrease in tumor growth in a 
xenograft mouse model of renal cancer (Xie H  et al, 2009).  
Interest in LDH as an anticancer therapeutic target also comes from the 
observation that, in normal cells, inhibition of LDH enzymatic activity should not 
cause harmful effects, as can be deduced by studying individuals with LDH 
genetic deficiencies; in fact it is known that patients with a hereditary deficiency 
of the A (Kanno T et al, 1988) or B (Motoshi K  et al,1971; Miwa S  et al, 1971; 
Okumura N et al, 1999) LDH isoform are free of symptoms, except for muscle 
rigidity and myoglobinuria, which can appear in individuals with LDH-A (Kanno 
T et al, 1988) deficiency after strenuous exercise. Overall, these observations  
encourage to study the validity of an anticancer therapeutic approach based on  
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LDH inhibition and justify the present efforts aimed at identifying small molecule 
inhibitors of this enzyme. 
 
Lactate dehydrogenase (LDH) 
 
LDH enzyme inter-converts pyruvate and lactate using nicotinamide adenine 
dinucleotide (NAD) as a cofactor. 
 
 
 
 
 
Figure 4. LDH enzymatic reaction. 
 
This (or similar) enzymatic activity has been characterized in organisms of the 
three domains of life (Archaea, Bacteria and Eukarya) (Madern D, 2002) and was 
evolutionarily conserved since it can be an important source of ATP and oxidized 
NAD for living organisms during periods of transient anaerobiosis. 
As well as the enzyme of other vertebrates, human LDH is a 140 kDa tetrameric 
molecule which exists in different isozymes, generally composed by the 
association of two different 35 KDa subunits (Markert CL et al, 1975). In 
vertebrates (including humans) three LDH-encoding loci have been identified in 
DNA: ldh-a, ldh-b and ldh-c, which produce the M (muscle) subunit, also named 
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LDH-A, H (heart) subunit, also name LDH-B and X subunit, respectively. The 
three genetic loci show 71-75% sequence identity, indicating extensive 
conservation in amino acid composition of the LDH subunits (Holmes RS et al, 
2009).  In humans, the X subunit is almost exclusively found in spermatozoa; the 
isozyme composed by X subunits is usually called LDH-C and has been supposed 
to play a role in male fertility (Yu Y et al, 2001). The association of M and H 
subunits can give rise to five isozymes: the tetramers H4, H3M1, H2M2, H1M3 
and M4.  
 
 
 
 
 
 
 
Figure 5. Lactate dehydrogenase M4. 
 
These five isozymes have different electrophoretic mobility, which is dependent 
on their H subunit content. H4 is the fastest moving form and for this reason it is 
also reported as LDH-1; on the contrary, the slowest form, M4, is also named 
LDH-5. The LDH forms enriched in M subunit predominate in skeletal muscle 
(fast twitch glycolytic fibers) and liver, while those enriched in H subunits are 
primarily found in heart and brain. LDH-A and –B also display different kinetic 
Introduction
 
 15 
properties (Read JA et al, 2001). LDH-A requires higher pyruvate concentrations 
to reach the maximum activity: the Km for pyruvate is 158 μM for LDH-A and 58 
μM for LDH-B (Eszes CM et al, 1996; Hewitt CO et al, 1999). Moreover, at 
substrate concentrations needed for optimal LDH-A activity, the –B isozyme is 
inhibited: the Ki for pyruvate is 770 μM for LDHB and 3900 μM for LDH-A 
(Eszes CM et al, 1996; Hewitt CO et al, 1999). 
On the basis of these differences, Kaplan (1975) hypothesized a different 
physiological function for the LDH isozymes (Everse J et al, 1975). He proposed 
the so-called “aerobic-anaerobic theory” which postulates that the B type of LDH 
is suited to aerobic metabolism, while the A type is more suited to tissues exposed 
to oxygen limitation, such as the overworking skeletal muscle. However, later 
data put into question this theory, since it was observed that human erythrocytes, 
which do not have mitochondria, predominantly synthesize LDH-B and that 
individual organs of different animal species display large differences in the LDH 
isozyme pattern. 
In normal conditions, the different LDH isozyme pattern expressed in tissues does 
not seem to play a different physiological role and in cytosol, in spite of their 
different kinetic parameters, both LDH-A and –B preferentially catalyze the 
reduction of pyruvate to lactate (Quistorff B et al, 2011). 
Since in most tissues the total enzymatic activity is high compared to the 
metabolic flux observed in steady state conditions, the LDH catalyzed reaction is 
always close to equilibrium and, as a consequence, both LDH-A and –B operate 
in the same way, as it is the same chemical reaction being catalyzed. LDH 
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reaction could significantly deviate from its equilibrium only during extensive 
changes in glycolytic flux and energy metabolism. Therefore, it is only in these 
situations that a different physiological role of the isozyme pattern can be 
perceived.  
LDH engaged in glycolysis is located in the cytosol; however, the enzyme is also 
present in peroxisomes, mitochondria and nuclei, where it exerts peculiar 
functions which so far may have not received due consideration in the studies 
aimed at inhibiting its activity. 
Peroxisomal LDH - In peroxisomes LDH is present in the matrix, where the A 
isoform predominates (Baumgart E et al, 1996; McClelland GB et al, 2003). One 
of the main function of peroxisomes is to shorten the longchain fatty acids (C > 
22), which cannot be handled by mitochondria. The NADH generated by β-
oxidation of the longchain fatty acid cannot be re-oxidized by the respiratory 
chain. A solid evidence was obtained that it can be reconverted to NAD by LDH 
in the presence of pyruvate (Baumgart E et al, 1996; McClelland GB et al, 2003). 
Lactate/pyruvate exchange is made possible by the monocarboxylate transporter 
present in the peroxisome membrane (McClelland GB et al, 2003). 
 Mitochondrial LDH – Glycolysis derived lactate can be re-oxidized and used as 
an energy source or as a precursor of gluconeogenesis (Brooks GA, 2009); re-
oxidation takes place in mitochondria and can occur both in the cells of origin and 
in adjacent or distant cells, after lactate release in extracellular medium. The 
facilitated transport of lactate across cell membranes is accomplished by a family 
of monocarboxylate transport proteins differentially expressed in tissues (Brooks 
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GA, 2009). Through these transporters, lactate can also gain access to 
mitochondria, where it is oxidized to pyruvic acid by the mitochondrial form of 
LDH. In mitochondria, pyruvate dehydrogenase rapidly metabolizes pyruvic acid, 
reducing its concentrations and favoring the oxidation of lactate by LDH. 
Nuclear LDH - Besides its widely known role in cell energy metabolism, the M 
subunit of LDH also displays an additional function in nuclei. Some years ago 
several authors observed that the LDH M subunit binds to single-stranded DNA 
(ssDNA) (Patel GL et al, 1980; Kaiserman HB et al, 1989). In analogy with what 
observed for other ssDNA-binding proteins (Shamoo Y, 2002) an involvement of 
the enzyme in DNA transcription and/or replication was suggested. This 
possibility was supported by the finding that nuclear LDH was localized on 
transcriptionally active regions of chromosomes (Patel GL et al, 1980; Williams 
KR et al, 1985). Moreover, the injection of the enzyme in cells of Chironomus 
salivary glands stimulated RNA synthesis in polytenic chromosomes, which on 
the contrary was inhibited by antibodies binding to LDH M subunit (Egyhazi E et 
al, 1989). More recently, a decisive proof of a role played by LDH in DNA 
transcription was obtained by Zhang, Luo and collaborators, who demonstrated 
that the enzyme is an essential component of the transcriptional complex of the 
histone 2B gene (H2B) (Dai RP et al, 2008). In this transcriptional complex, LDH 
M subunit is in association with glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and the coordinated activity of the two enzymes maintain the proper 
NAD/NADH ratio necessary for optimal H2B expression (Dai RP et al 2008; He 
H et al, 2013). In contrast with cytoplasmic LDH, for which the minimal 
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functional unit was shown to be a dimmer (Wang XC et al, 1987), the nuclear 
enzyme is monomeric and is presumably maintained catalytically active by the 
supramolecular structure formed with GAPDH and with the other components of 
the transcriptional complex. GAPDH and LDH monomers were also found to 
form catalytically active complexes in vitro (Levashov AV et al, 1997). Since 
LDH M subunit is widely distributed within cell nuclei (Cattaneo A et al, 1985), 
its involvement in regulating the transcription of other genes cannot be excluded; 
these observations suggest that LDH could also participate in regulating survival 
pathways and that its inhibition in anticancer treatment might have effects not 
simply limited to the energy metabolism of transformed cells. 
   
 
 
 
 
 
 
 
Modified  from Kim JW and Dang CV, 2005 
Figure 6.  LDH in  the transcriptional complex of  the histone 2B gene. 
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The search for LDH inhibitors 
 
The success of a therapeutic approach based on LDH inhibition chiefly depends 
on the availability of inhibitors with good target specificity. Unfortunately, in 
spite of extensive research, LDH proved to be a very difficult target for the 
development of new inhibitors, since all high throughput screening experiments 
have been usually characterized by a very low success rate (Ward et al, 2012). 
One of the approaches adopted in the search of small molecules which could 
inhibit LDH enzyme is represented by the modification of already known 
inhibitors, like oxamic acid and gossypol, two longtime known inhibitors, 
displaying no selectivity between the –A and –B LDH isoforms. Oxamic acid is  
an analogue of pyruvic acid, the enzyme substrate. Although displaying a good 
selectivity for LDH (Papacostantinou and Colowick, 1961a) and a weak toxicity 
in healthy animals (Papacostantinou and Colowick, 1961b), oxamic acid has the 
drawback of a poor cellular penetration; as a consequence, it was found to inhibit 
the proliferation of tumor cells cultured in vitro only at millimolar concentrations, 
which cannot be expected to be reached in vivo.  Starting from oxamic acid as a 
lead compound, some libraries of derivatives have been created, with the aim of 
improving the therapeutic potential of the molecule. Several of these molecules 
were synthesized and tested on LDH of Plasmodium falciparum, a parasite which 
relies on aerobic glycolysis for its energetic needs in order to improve the 
chemotherapy of malaria (Choi S  et al, 2007; Deck LM  et al, 1998).  
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Encouraging results were also obtained on the α-hydroxyacid dehydrogenase 
(HADH) of Trypanosoma cruzi, which shows similarities with the human LDH-C. 
Simple derivatives of oxamic acid such as N-isopropyl and N-propyl oxamate 
were found more active in inhibiting HADH in vitro than the parent compound 
and their ethyl-ester pro-drugs orally administered to Trypanosoma cruzi infected 
mice also demonstrated therapeutic efficacy in vivo (Aguirre-Alvarado C et al, 
2007). To our knowledge, no oxamic acid derivative with anticancer potential has 
been identified with this approach. 
Gossypol is a natural polyphenolic aldehyde derivative found in cotton seeds and 
it is a well-known nonselective LDH inhibitor competitive with NADH. However, 
it also inhibits other NAD-dependent enzymes such as glyceraldehydes-3-
phosphate dehydrogenase (GADPH) (Gomez MS et al, 1997). Moreover, because 
of its structural characteristics gossypol can interact with different cellular 
components affecting several biological functions, which causes unspecific 
toxicity (Dodou K  et al 2005; Lee CY  et al, 1982). Contrary to oxamic acid, it 
displays in vitro activity at the micromolar level; for this reason, many gossypol 
analogues have been designed with the aim of reducing the molecule toxicity. The 
most promising one is a derivative called FX-11, selected as a potential anticancer 
drug for its ability to preferentially inhibit the A isoform of LDH (Le A et al, 
2010). Furthermore, it was demonstrated that FX-11-mediated inhibition of LDH-
A negatively affected cellular energy supply by depleting ATP levels, diminished 
cellular production of lactate, induced oxidative stress, and caused cell death. FX-
11 also decreased growth in tumor xenograft models, such as human lymphoma 
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and pancreatic cancer (Le A et al, 2010). However, further studies have 
challenged the validity of FX-11, giving rise to the suspicion that some of the 
observed effects could be not specifically ascribed to LDH inhibition, but to the 
reactive nature of the catechol group of the molecule (Kohlmann A  et al, 2013; 
Lee CY  et al, 1982). 
Another commonly procedure adopted for the search of pharmacologically active 
molecules that potentially could inhibit LDH is the  screening of already 
established compound collections by using high throughput technologies. It was 
recently employed by researchers from Genentech Inc., who tested for LDH-A 
inhibition the compounds available in their own Company Repository and in the 
Roche collections. This screening identified 2-thio-6-oxo-1,6-dihydropyrimidine 
as a moderately potent LDH-A and LDH-B inhibitor, with only weak effects on 
other structurally related dehydrogenases, suggesting some specificity for LDH. 
In following experiments, a series of chemical modifications were introduced in 
the molecule structure with the aim of improving its LDH-A inhibition properties. 
Unfortunately, none of the obtained inhibitors, tested on cultured cell up to 50 
μM, was found to reduce lactate production (Dragovich PS et al, 2013); additional 
studies are then needed to improve the biological properties of these inhibitors. 
Recently  researchers from GlaxoSmithKline announced the discovery of 
quinoline 3-sulfonamides as potent (nanomolar) LDH inhibitor, with good 
selectivity towards the A isoform (Billiard J et al, 2013). The details of the high 
throughput screening procedure leading to this discovery are at present un-
published. 
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Moreover another strategy to find new potential LDH inhibitors is that adopted by 
a research team from the University of Pisa, which used an ex-novo design 
method to obtain new chemical structures by inserting –OH and –COOH groups 
into a N-hydroxyindole (NHI) scaffold (Granchi C et al, 2011). These compounds 
were designed on the basis of the “OH-COOH” pharmacophore motif often 
present in previously reported LDH inhibitors, as the active site normally hosts an 
α-hydroxy group (lactate) or an α-keto acid (pyruvate). 
Several molecules obtained with this procedure were found to inhibit the lactate 
production in cancer cells, but no further experiments were performed with this 
class of compounds; a thorough examination of their biological characteristics 
would be useful to better evaluate their potential. 
Fragment-based lead generation also proved to be a successful approach with a 
number targets (Rees DC et al, 2004). It requires a preliminary screening aimed at 
identifying small chemical fragments which, although not inhibiting the activity 
of target protein, show the property of binding to critical sites needed for its 
function, as, in the case of LDH, the NADH and the pyruvate binding regions. 
This preliminary selection is usually performed with the aid of NMR spectroscopy 
and/or surface plasmon resonance. The identified fragments are then linked 
together by the use of flexible spacers, yielding compounds with greatly improved 
potency and selectivity. This approach has been applied the first time to the search 
of LDH inhibitors by Moorhouse et al (Moorhouse AD et al, 2011). More 
recently, it has been simultaneously used by two different teams of researchers, in 
Astra-Zeneca and ARIAD Laboratories. By using this approach, Astra-Zeneca 
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researchers succeeded in obtaining some of the most potent LDH inhibitors now 
available (Ward RA et al, 2012);  in particular the most active molecule showed in 
the enzyme inhibition assay a IC50 as low as 0.27 μM, but, unfortunately, was 
reported to lack activity in cell based assays, probably because of scarce cellular 
penetration. However, its dimethyl ester derivative, although displaying reduced 
enzyme inhibitory potency compared to the parental compound, was found to 
inhibit lactate production in cultured cells (IC50 = 4.8 μM). Researchers at 
ARIAD Pharmaceuticals obtained similarly potent molecules (Kohlmann A et al, 
2013); one of the most promising was able to heavily reduce lactate production in 
cultured cells, although at rather high doses (200 μM). 
Both the Astra-Zeneca and the ARIAD study are quite recent and to our 
knowledge further published reports are still lacking. New advances leading to the 
generation of more bioavailable molecules are expected, to make possible the start 
of anticancer experiments in vivo. 
Finally, the structure-based virtual screening approach is a further method to 
search new LDH inhibitors. My research team in collaboration with the 
Department of Pharmaceutical Sciences of the University of Bologna, by adopting 
a virtual screening protocol based on the crystal structure of the human M subunit 
of LDH and applied to the molecules of the National Cancer Institute diversity set, 
identified a molecule, named galloflavin which is able to inhibit both the –A and –
B LDH isoforms. The description of this new inhibitor and all its effects, showed 
in several cellular models, are presented in this thesis. 
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Impairment of Aerobic Glycolysis by Inhibitors of Lactic 
Dehydrogenase Hinders the Growth of Human Hepatocellular 
Carcinoma Cell Lines 
 
According to the finding of Warburg (Warburg O, 1930), reevaluated in recent 
years (Garber K, 2006) neoplastic cells derive much of their energy for survival 
and growth from aerobic glycolysis. 
Lactate dehydrogenase (LDH) is the only glycolytic enzyme whose inhibition 
should allow a blocking of the aerobic glycolysis of tumor cells without damaging 
the normal cells which, in conditions of normal functional activity and sufficient 
oxygen supply, do not need this enzyme (Fiume L, 1969; Papacostantinou J and 
Colowick SP, 1961a). 
In this preliminary work my research team and I demonstrated that oxamic acid 
and tartronic acid, two LDH competitive inhibitors, impaired aerobic glycolysis 
and replication of HepG2 and PLC/PRF 5 cells, two lines derived from a well 
differentiated and a poorly differentiated human hepatocellular carcinoma (HCC), 
respectively (Aden DP et al, 1979; Alexander JJ et al, 1976). 
We have also shown that oxamic acid impairs cell growth by only inhibiting 
aerobic glycolysis, without interfering with Krebs cycle. Cultured cells derive 
their energy from glucose metabolism and glutamine oxidation. When cells are 
posed in a glucose free medium, they can not glycolyse and almost completely 
rely for their survival and growth on glutamine oxidation. 
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We found that under these conditions oxamic acid practically do not affect HepG2 
and PLC growth, indicating that this compound does not interfere with the Krebs 
cycle and that the growth inhibition caused by oxamic acid when cells are 
cultured on glucose could be attributed to the impairment of aerobic glycolysis; on 
the contrary tartronic acid was shown to interfere with glutamine oxidation and 
this interference might be due to the inhibition of mitochondrial malic 
dehydrogenase (Harada K et al, 1968). 
Moreover the increased expression of the p53-Upregulated Modulator of 
Apoptosis (PUMA) indicated that the block of aerobic glycolysis resulted in the 
death of the cells. 
The present data are in agreement with those of Papaconstantinou and Colowick 
(Papaconstantinou J and Colowick SP, 1961b), who studied the effect of oxamic 
acid on HeLa cell replication and fit in with the finding that mammary tumor cell 
lines in which LDH activity was reduced by means of short hairpin RNA showed 
a retarded rate of cell proliferation (Fantin VR et al, 2006). 
In conclusion, inhibition of aerobic glycolysis achieved by blocking LDH could 
be useful in the treatment of human hepatocellular carcinomas. Without 
interfering with glucose metabolism in normal cells, it could hinder cell growth by 
itself and could also enhance the chemotherapeutic index of associated anticancer 
agents by decreasing the levels of ATP selectively in neoplastic cells. 
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Inhibition of lactic dehydrogenase as a way to increase the anti-
proliferative effect of multitargeted kinase inhibitors 
 
Protein kinases play a critical role in the modulation of growth factor signalling. 
Activated forms of these enzymes can cause increase of tumor cell proliferation, 
induce apoptotic effects and promote angiogenesis and metastasis. Because these 
effects are initiated and proceed through by a sequential activation of proteins of 
the kinase family, these enzymes are a good target for anticancer treatment (Arora 
A et al, 2005). Multi-targeted inhibitors of protein kinases are an emerging class 
of antineoplastic agents. They are quite recently developed compounds, whose use 
will likely increase in the next future because of broad spectrum antitumor 
activity, ease of administration and good tolerability. Most of them are small 
molecules which bind to the ATP site on the protein kinases target of their activity 
(Sebolt-Leopold JS and English JM, 2006). 
We considered the possibility that a decrease of ATP levels in neoplastic cells 
could reduce the competition for the same enzymatic site, thus increasing the 
efficacy of the kinase inhibitors. To explore this possibility, in this work it was 
studied on PLC/PRF/5 cells the effect of three commonly used kinase inhibitors 
(sorafenib, sunitinib and imatinib) given alone or in combination with oxamic 
acid, an LDH inhibitor. PLC/PRF/5 cells derived from HCC (Alexander JJ et al, 
1976) and were an appropriate model to perform this study since this tumor is 
often refractory to chemotherapeutic interventions and even the benefit observed 
with the introduction of kinase inhibitors (sorafenib) was modest, so that the 
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search for new and more effective therapeutic alternatives for treating HCC is still 
ongoing. 
As a first step to verify our experimental hypothesis, cell viability assays were 
performed to evaluate the antiproliferative effect on PLC/PRF/5 cells of the 
kinase inhibitors given alone. To test their effect when given in combination with 
oxamic acid, for each kinase inhibitor we selected doses causing a statistically 
significant inhibition on PLC/PRF/5 cell proliferation, not higher than 30%, in 
order to facilitate the evidence of a possible potentiating effect in the association 
with oxamic acid. In subsequent experiments the selected doses of kinase 
inhibitors (sorafenib 8-16 μM, sunitinib 8 μM; imatinib 32 μM) were combined 
with oxamic acid. Oxamic acid was used at concentrations of 60 and 80 mM 
which block aerobic glycolysis and reduce cellular ATP levels, but causing 
minimal effects on cell growth, not higher than 20% (Fiume L et al, 2010).  
When the kinase inhibitors were given in combination with oxamic acid, an 
enhancement of their anti-proliferative effect was observed, that, for the 80 mM 
dose, always resulted statistically significant when compared to the effect of the 
kinase inhibitor given alone. In the case of 16 μM sorafenib, the combination with 
80 mM oxamic acid had a so heavy effect to bring about the almost complete 
inhibition of cell growth (> 97%) over the 24h. 
Morphological examination of treated cells confirmed the potentiating effect 
exerted by the drugs association. It was performed only on cells treated with 
sorafenib since, compared to the other kinase inhibitors, the gain of efficacy 
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observed with the oxamic acid association of this compound was the most 
remarkable.  
Moreover to confirm the enhanced effect produced by the oxamic acid / sorafenib, 
we also evaluated the phosphorylation level of ERK protein, involved in the 
MAPK kinase signalling pathway. One of the primary targets of sorafenib is RAF 
kinase, the first signalling element of MAPK pathway, which has an essential role 
in HCC cell proliferation (Liu L et al, 2006). Blocking of RAF causes a 
downstream reduction of MEK and ERK phosphorylation, ultimately resulting in 
the inhibition of cell proliferation. 
By immunoblot analysis we observed that 1h treatment with 16 μM sorafenib 
reduced the phosphorylation of ERK1/2 and 80 mM oxamic acid given for 1h to 
PLC/PRF/5 cells did not affect ERK phosphorylation, which on the contrary was 
heavily reduced in cultures treated with the 16 μM sorafenib / 80mM oxamic acid 
association, where the low molecular weight band of phosphoERK was not 
detected. The further reduction of phosphoERK observed in these cells, compared 
to those treated with sorafenib alone, is a confirm of the enhancing effect caused 
by oxamic acid on the signalling inhibition produced by sorafenib.  
According to the rationale which suggested these experiments, the enhanced 
antiproliferative effect of oxamic acid association with kinase inhibitors can at 
least in part be due to the reduced number of ATP molecules competing with the 
drugs for the binding to the common enzymatic site. 
We showed that when aerobic glycolysis was shut down by culturing PLC/PRF/5 
cells on galactose (Reitzer LJ et al, 1979; Rossignol R et al, 2004), oxamic acid 
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did not cause a depletion of ATP, indicating that this compound does not interfere 
with the oxidative phosphorylation, still operative in this culture condition. As a 
consequence, in glycolysing cells the reduced ATP concentrations caused by 
oxamic acid can only be ascribed to the inhibition of aerobic glycolysis. This 
suggests that in normal cells, which do not produce ATP through aerobic 
glycolysis, the inhibition of LDH should not exacerbate the adverse reactions of 
antineoplastic drugs.  
Oxamic acid is a non toxic substance in laboratory animals, up to 3g/kg 
(Papaconstantinou J and Colowick SP, 1961b). On the other hand, it inhibits the 
aerobic glycolysis of cells cultured in vitro only at high concentrations, which are 
about 1000 times higher than those active on LDH from cell free extracts and can 
not expected to be reached in vivo.  
However, changes of the molecule can be studied using oxamic acid as a lead 
compound to synthesize a selective and more powerful inhibitor of LDH. A 
similar attempt was performed to improve the chemotherapy of malaria, by testing 
several derivatives of the oxamic acid molecule on LDH of Plasmodium 
falciparum, a parasite which relies on aerobic glycolysis for its energetic needs 
(Choi S et al, 2007; Deck LM et al, 1998). Encouraging results are also those of 
experiments addressed to the inhibition of the isoform II of α-hydroxyacid 
dehydrogenase (HADH II) of Trypanosoma cruzi, which shows a substrate 
specificity similar to that of LDH-C4 of spermatozoa. Moreover, by applying the 
virtual screening procedure (Rester U, 2008) to the crystal structure of human 
LDH, also molecules chemically unrelated to oxamic acid but able to inhibit LDH 
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can be searched; therefore the results of our experiments encourage the search for 
a LDH inhibitor more powerful than oxamic acid and also active in vivo. Its 
association with kinase inhibitors could enhance the anti-proliferative efficacy of 
these drugs in the treatment of responsive tumours without increasing their side 
effects on normal cells, which in conditions of normal functional activity and 
sufficient oxygen supply do not need the activity of this enzyme. 
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Effect of sorafenib on the energy metabolism of hepatocellular 
carcinoma cells 
 
In our previous work (Fiume L et al, 2011) we demonstrated that oxamic acid, an 
inhibitor of lactate dehydrogenase, potentiated the activity of multitargeted kinase 
inhibitors (sorafenib, sunitinib, imatinib), by depleting ATP thus reducing the 
competition for the common enzymatic site; in particular we observed the most 
marked effect with the association oxamic acid /sorafenib. The enhancing effect 
caused by oxamic acid on the signalling inhibition produced by sorafenib could 
represent an interesting result because to date it is the only drug used for 
hepatocellular carcinomas (HCCs) chemotherapy, even though it produced only 
modest results on patient survival (Llovet JM et al, 2008).  
Recent data demonstrated that sorafenib impaired the oxidative phosphorylation 
(OXPHOS) of a rat myogenic cell line and suggested that this biochemical lesion 
can contribute to the cardiac toxicity caused by the drug (Will Y et al, 2008). In 
this paper, we studied whether this mechanism of cell damage can also take  part 
in the anti-proliferative effect of sorafenib.  
We elucidated that sorafenib at the concentrations raised in plasma of patients 
treated with the drug (4-8 uM) decreased the oxygen comsuption in PLC/PRF 5 
and SNU-449 cell cultures, two lines derived from human HCCs (Alexander JJ et 
al, 1976; Park JG et al, 1995).  
We also showed that in glycolysing cells the mitochondrial ATP depletion, caused 
by sorafenib, stimulated aerobic glycolysis, as indicated by the higher amount of 
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lactic acid formed in the presence of the drug. Moreover when the cell coltures 
were treated with the association oxamic acid/sorafenib, both the metabolic 
pathways were inhibited, and only after 3 hours of exposure, it could be observed 
a drastic decrease of ATP levels. Because of the link between the two energetic 
pathways (Krebs HA, 1972), as stated above, the depletion of mitochondrial ATP 
in glycolysing cells caused an increase of glycolysis so that the ATP content in 
these cells was only 12–32% lower than that of control cells. This decrease, 
although moderate, is statistically significant and can impair cell growth, as 
supported by the finding that in both cell lines a dose of oxamic acid which 
reduces ATP levels to the same extent as sorafenib after a 3 days exposure 
significantly reduced the number of viable cells by about 30%. Moreover, in the 
case of sorafenib, which blocks the target kinases by binding to their ATP sites 
(Sebolt-Leopold JS and English JM, 2006), the depletion of ATP could also 
enhance the anti-kinase activity of the drug by reducing the competition for the 
common enzymatic site. Therefore, the present results point out that the loss of 
ATP caused by the drug interference with OXPHOS probably contributes to the 
anticancer activity of sorafenib on human HCC cells.  
The observation of an increased ratio between glycolytic and OXPHOS-derived 
ATP in HCC cells treated with this drug suggests that a possible way to enhance 
the therapeutic power of sorafenib could be its combination with glycolytic 
inhibitors, such as oxamic acid, which blocks LDH. Unfortunately, oxamic acid 
has the drawback of a scarce cellular penetration and, consequently, it inhibits 
aerobic glycolysis at concentrations which cannot be reached in vivo. However, 
General discussion 
 
 104 
our results encourage the search of novel LDH inhibitors more potent and active 
in vivo than the oxamic acid and they will probably be available for clinical trials 
in the near future. Their administration in combination with sorafenib could be a 
worthwhile attempt to enhance the results of HCC chemotherapy. 
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Galloflavin (CAS 568-80-9): A Novel Inhibitor of 
Lactate Dehydrogenase 
 
The inhibition of lactate dehydrogenase (LDH) is a promising way to inhibit 
tumor cell glucose metabolism without affecting the energetic balance of normal 
tissues. However, the success of this approach depends chiefly on the availability 
of inhibitors that display good selectivity. 
The only well-characterized and specific inhibitor of LDH is oxamic acid which 
displays a good selectivity for LDH and weak toxicity in healthy animals, 
although has the drawback of poor cellular penetration (Papaconstantinou J and 
Colowick SP, 1961b) . In our previous works (Fiume L et al 2010; Fiume L et al, 
2011), we studied its effect in neoplastic cells and we confirmed its ability in 
hindering aerobic glycolysis. Our results suggest that, research using drug design 
technologies to find a strong and selective LDH inhibitor hindering aerobic 
glycolysis also in vivo, can be a worthwhile attempt to improve the common 
antineoplastic chemotherapy. 
In this work we described the identification of a novel LDH inhibitor, galloflavin, 
a gallic acid derivative, which was selected by virtual screening of a molecular 
dataset and carefully biologically characterized. This approach, adopted by our 
colleagues of the Department of Pharmaceutical Sciences, was based on the 
crystal structure of  the A isoform of LDH, obtained from the Protein Data Bank 
and it was applied to the molecules of the National Cancer Institute diversity set 
and led to the identification of  20 putative inhibitors, which were subsequently 
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tested on the purified human enzyme. Only five of them were found to cause 
enzyme inhibition at micromolar level. The compounds are: galloflavin 
(NCS107022), lomofungin (NCS156939), redoxal (NCS73735), vanillil 
(NCS16722), and nortangeretin (NCS76988). According to the information in the 
PubChem database, neither LDH inhibitory activity nor other effects on glycolytic 
enzymes have been reported yet for these compounds. For each compound we 
calculated the minimum dose required for complete inhibition of enzyme activity 
(IC100). Although less commonly used than IC50, this parameter was chosen 
with the aim of identifying a fully active inhibitor dose for testing on cells 
cultured in vitro for preliminary evaluation of their biological activity. The IC100 
values calculated for LDH-A were tested with PLC/ PRF/5 cultures to evaluate 
their effect on lactate production, cell respiration, ATP levels, and cell 
proliferation; galloflavin was found to reduce the lactate production, proving good 
cell permeability. Moreover, it was shown to be not harmful for mitochondrial 
respiration, suggesting tolerability for normal cell metabolism. 
Among the other compounds, vanillil was not deemed worthy of further study, as 
it caused only a small decrease in lactate levels and did not affect cellular ATP 
and PLC/PRF/5 growth. The remaining three compounds (redoxal, lomofungin, 
and nortangeretin), added to the assay cell cultures at their respective LDH IC100 
values, hindered oxygen consumption, denoting lack a of specificity toward this 
enzyme. From our biological evaluations, galloflavin proved to be the only 
potentially useful LDH inhibitor. Therefore, a more detailed characterization of its 
biological properties was performed. 
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The docking made with human LDH-A isoform showed that galloflavin 
apparently binds mainly to the enzyme by hydrogen bonds. In particular, the 
carbonyl oxygen atoms of galloflavin act as hydrogen bond acceptors with Thr247 
and Gln 99, and the compound’s hydroxy groups establish hydrogen bond 
interactions with Asn137 and Ala 95. Finally, the 9- hydroxy group could make 
contact with either Ala 97 or Asn112 and with the backbone nitrogen atom of Asn 
137 as well. Galloflavin was also docked into the human LDH-B isoform, and a 
pose quite similar to that observed with human LDH-A was found. This was not 
unexpected, considering the high sequence similarity (~75%) (Granchi C et al, 
2010) of the binding site domains. 
Galloflavin was found to inhibit both the isoform A and B of LDH and to 
determine the mechanism of action, we collected LDH-A and -B inhibition data in 
competition reactions with the substrate (pyruvate) or the cofactor (NADH) and 
evaluated the results using software for enzyme kinetics analysis. We found that 
galloflavin inhibited both human LDH isoforms by preferentially binding the free 
enzyme, without competing with the substrate or cofactor. The calculated Ki 
values for pyruvate were 5.46 mm (LDH-A) and 15.06 mm (LDH-B). 
The discovery of galloflavin’s inhibitory action against both human LDH 
isoforms suggests broader and more interesting properties than those of some  
inhibitors, which were found to act specifically on LDH-A (Yu Y et al, 2001; 
Granchi C et al, 2011). In fact, data were recently reported that indicate a pivotal 
role for LDH-B in tumorigenesis mediated by hyperactive mTOR (mammalian 
target of rapamycin) signaling (Zha X et al, 2011). 
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We calculated that the concentration of galloflavin causing a 50% decrease in 
lactate production is 140 μM. This dose fits well with the concentration required 
to decrease cell viability by 50% (184 μM), suggesting that in PLC/PRF/5 cells 
exposed to galloflavin, the decrease in viability could be ascribed mainly to 
inhibition of aerobic glycolysis caused by the compound.  However these doses 
(140–184 μM) reduced ATP levels by only 25-30%. This result can be easily 
explained by considering that even in cells where glycolysis is active, 
mitochondrial function is not completely abolished and that mitochondrial 
respiration is more productive in ATP synthesis than glycolysis.  This limited 
effect on ATP levels appeared to have a positive consequence, as by studying the 
cell death mechanism triggered by galloflavin, we observed the induction of 
apoptosis, with no evidence of necrosis caused by a deep ATP depletion. 
To our knowledge, the inhibition of LDH isoenzymes is the only biochemical 
effect described for galloflavin. Preliminary toxicity data for this molecule are 
available from the NCI (http://dtp.nci.nih.gov/), and remarkably they suggest 
good tolerability: in mice the maximum tested dose (400 mgkg
_1
 injected i.p.) did 
not produce lethal effects. 
In conclusion, galloflavin was found to be a promising lead candidate in the field 
of tumor metabolism inhibitors and led us to continue with further studies aimed 
at better define its therapeutic potential.  
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Galloflavin, a new lactate dehydrogenase inhibitor, induce the 
death of human breast cancer cells with different glycolytic 
attitude by affecting distinct signalling pathways 
 
After the identification of galloflavin, a new lactate dehydrogenase (LDH)  
inhibitor (Manerba M et al, 2012), the aim of our next work was to investigate the 
effects of this compound on cells from tumors of different pathological subtypes, 
suggestive of a different metabolic state of the transformed cells. As a model for 
our study we chose human breast cancer, a neoplasm which is known to exhibit 
remarkable heterogeneity in phenotype, usually classified by reporting the 
expression profile of ER, PR and HER-2. The MCF-7 cell line was used as a 
model of the well differentiated human breast cancer (ER and PR positive) and 
the MDAMB-231 as representative of the more aggressive triple-negative form of 
the tumor. The experiments were also performed on a sub-line of MCF-7, in 
which ER function has been lost. This line (MCF-Tam) was obtained by 
maintaining the parental cells in the presence of clinically relevant levels of 4-
hydroxy-tamoxifen (10
_7
 M) (Farabegoli F et al, 2007) and showed an activated 
EGFR signalling pathway (Farabegoli F et al, 2010). 
As first we characterized these three cell lines by quantifying their LDH 
enzymatic activity, glucose uptake, lactate production and relative oxygen 
consumption and we observed that they showed marked differences in the 
metabolic profile; in particular, MDAMB-231 and MCF-Tam exhibited a 
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phenotype more dependent on glycolysis, contrary to MCF-7 in which oxidative 
phosphorylation remained still operative. 
The data reported in this paper showed that, in spite of the differences in the 
metabolic profile observed in the three lines, the effect of galloflavin on the cell 
growth was quite similar and this result could be in conflict with the much higher 
glycolysis dependence shown by MDA MB-231  and MCF-Tam; only later we 
showed that it could be justified by other characteristics of these cells. In this way, 
we continued investigating about the different antiproliferative mechanisms which 
contribute to cell death in the three cell lines; in particular, we wanted to evaluate 
if galloflavin, by depleting ATP levels, could down-regulate the signalling 
pathway involved in cell survival, and if this compound could be responsible for 
the induction of stress oxidative in the treated cultures.  
In previous studies LDH inhibition was in fact found to induce reactive oxygen 
species (ROS) generation, as a consequence of a compensatory increase in cell 
respiration set out by cells attempting to restore their ATP supply (Le A et al., 
2010). These effects were studied by incubating breast cancer cell cultures to the 
mean IC50 dose of galloflavin (125 μM). 
While in MCF-7 galloflavin 125 μM, by depleting ATP levels, caused a down-
regulation of the expression of mRNA of ERα, thus depriving cells of the most 
important survival signal (Levenson AS and Jordan VC, 1997), in MDA-MB-231 
and MCF-Tam galloflavin was found to activate a stress response as a result of 
increased ROS generation. In this case, the highly glycolysing MDA-MB-231 and 
MCF-Tam cells were not able to cope with the ATP depletion caused by LDH 
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inhibition by simply increasing the mitochondrial function and the induction of 
the oxidative stress is a possible cause contributing to the growth inhibition. The 
activation  of the stress-response pathway in these cells was witnessed by the 
statistically significant increase of  JNK and p38 phosphorylation. The study of 
phospho-JNK and phospho-p38 expression also allowed to explain why, in spite 
of their much higher glycolysis dependence, MDA-MB-231 and MCF-Tam did 
not exhibit higher sensitivity to the antiproliferative effects of galloflavin. In these 
cells, which are representative of aggressive forms of breast cancer, the stress 
response pathway is constitutively activated, since both JNK and p38 appeared 
phosphorylated also in the untreated cultures. This constitutive activation can 
render the cells less susceptible to harmful stimuli (Davidson B et al., 2006). 
Finally, these different antiproliferative mechanisms led to the apoptosis induction 
in all the three cell lines. 
As shown by our results, galloflavin inhibits the growth of breast cancer cells at 
higher dose (125 μM) compared to commonly used chemotherapeutics. However 
we demonstrated that non neoplastic cells present a better tolerability to 
galloflavin as compared with breast cancer cells, by studying its effect on 
lymphocytes from peripheral blood and GM130C human lymphoblasts. These 
data, together with those ones on galloflavin toxicity available from NCI web site 
(http://dtp.nci.nih.gov/), suggesting a good tolerability in mice, offers a good 
motivation to test this new inhibitor on other cellular models in order to continue 
defining its therapeutic potential. Our results on breast cancer cells confirm that 
the inhibition of  bioenergetic metabolism obtained by LDH blockage is a 
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promising therapeutic strategy. Moreover they agree with other several previously 
published data indicating that LDH play a critical role on growth properties and 
tumor maintenance of breast cancer cells (Nagai MA et al, 1988; Zaho YH et al, 
2009) and  with other two works in which inhibition of LDH-A was found to be  a 
way to overcome the acquired resistance of breast cancer cells to taxol (Zhou M et 
al, 2010) and trastuzumab (Zhao X et al, 2011). 
In spite of the unquestionable progresses achieved in breast cancer therapy, the 
treatment of some forms of this tumor, such as the triple negative or the drug 
resistant lesions, still poses a challenge to the clinical oncologists.  In this context, 
our observation of galloflavin activity even on the breast cancer cells which 
mimic these tumor forms with unfavorable prognosis, for its clinical relevance 
adds further interest in the properties of this compound. 
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Galloflavin suppresses lactate dehydrogenase activity and causes 
MYC downregulation in Burkitt lymphoma cells through 
NAD/NADH dependent inhibition of sirtuin-1 
 
In this paper we continued investigating about the effects caused by galloflavin  
on the observation that  aerobic glycolysis, is the consequence of oncogenes and 
oncosuppressors reprogramming the cellular energetic machinery (Levine AJ and 
Puzio-Kuter AM, 2010). One of the most characterized DNA alteration that 
induces glycolytic phenotype in cancer cells is the activation of the myc oncogene 
(Dang CV et al, 2009). 
MYC is a helix–loop–helix leucine zipper transcription factor that dimerizes with 
its partner protein MAX. The dimer then binds to specific DNA sequences and 
transactivates genes involved in cell proliferation, differentiation, and apoptosis. 
Further, MYC plays an important role in the regulation of glucose metabolism 
(Kim JW and Dang CV, 2006). It directly transactivates the A subunit of lactate 
dehydrogenase (LDH-A), which is directly involved in myc-mediated cell 
transformation (Dang CV et al, 2009; Shim H et al, 1997). 
The myc-dependent linkage between altered cellular metabolism and 
tumorigenesis (Dang CV et al, 2009; Kim JW and Dang CV, 2006) prompted us 
to investigate the effects of galloflavin-mediated LDH inhibition in myc- 
hyperexpressing cancer cells. Thus, we studied the effects of galloflavin on 
Burkitt’s lymphoma (BL) cells (Raji, Daudi, Loukes), representing a tumor 
characterized for the 90% of cases by myc overexpression, in addition to a 
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chromosomal translocation (the most common translocation is t(8:14)) (Slack GW 
and Gascoyne RD, 2011). 
Our data indicated that myc overexpression in BL cells increased the expression of 
the LDH-A subunit, which is normally expressed at low levels in this cell type. 
Compared to other tumor models, BL cells were found to be very susceptible to 
galloflavin effects (IC 50~30 uM), while on two non neoplastic lymphoblastoid 
cell lines used as control (GM130C and AG3138A) the effect of galloflavin was 
not statistically significant. However, we found that higher LDH-A levels do not 
drive cell metabolism toward glycolytic ATP generation, and this observation was 
an unexpected result. In fact, galloflavin  at doses that cause a 50% reduction in 
cell growth and lactate production, did not affect ATP levels in any of the three 
BL cell lines, suggesting that in these cells oxidative phosphorylation remains 
operative and can be a source of ATP supply. 
Since in these cells the growth inhibition is not to be ascribed to the ATP 
depletion, we tried to investigate to find another possible antiproliferative 
mechanism. For this purpose, we considered only Raji cell cultures, as these cells 
were more sensitive to galloflavin, but their ATP levels were essentially 
unaffected by galloflavin treatment.  
In aerobic glycolysis, the LDH enzyme functions to regenerate oxidized NAD, is 
necessary for sustained glucose degradation. NAD participates in multiple 
metabolic reactions as a cofactor, and it can also mediate biologic processes by 
acting as a substrate for a wide range of proteins (Houtkooper RH et al, 2010; Lin 
SJ et al, 2003). Among the NAD-consuming enzymes, sirtuins, particularly, 
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SIRT1, have high Km values for NAD (Houtkooper RH et al, 2010). Therefore, 
these enzymes are highly susceptible to changes in the cellular levels of this 
dinucleotide. 
SIRT1 is a histone deacetylase that promotes cell survival under stressful 
conditions by deacetylating key cell cycle molecules and apoptosis regulatory 
proteins, including p53 (Li K and Luo J, 2011; Milner J, 2009). Several reports 
have revealed that SIRT1 is upregulated in various human tumors (Milner J, 
2009), including B-cell lymphoma, for which enhanced expression of this protein 
was detected in greater than 70% of patients (Jang KY et al, 2008). Moreover, 
previous studies have demonstrated that the MYC protein is a substrate of SIRT1, 
which deacetylates MYC and promotes its transcription factor functions (Mao B 
et al, 2011). On the basis of this knowledge, we investigated the effect of 
galloflavin on MYC protein levels and SIRT1 activity. In the absence of a 
commercially available, specific, acetyl-MYC antibody, SIRT1 activity was 
evaluated by measuring the acetylation levels of the p53 protein, a known SIRT1 
target (Li K and Luo J, 2011). 
We observed that galloflavin at 50 μM markedly affected the NAD/NADH 
balance in Raji cells causing a four-fold reduction in NAD levels and an increase 
in NADH levels. Furthermore galloflavin led to  a notable decrease of MYC 
protein levels and an increase in p53 acetylation, which is indicative of SIRT-1 
inhibition. Since myc activity is related to its protein levels (Sachaf GM et al, 
2008), these data suggest that galloflavin can suppress MYC-driven signals in 
Raji cells. 
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The same experiments were also conducted on the GM130C lymphoblastoid cell 
line as a control and interestingly, MYC protein levels and p53 acetylation were 
unaffected in GM130C cells exposed to 100 μM galloflavin. 
Since galloflavin is a recently identified LDH inhibitor, and other effects than 
LDH inhibition cannot be excluded, to verify whether its effects observed on Raji 
cells were a result of LDH inhibition, we treated Raji cultures with oxamic acid 
(OXA), a known specific inhibitor of this enzyme. OXA inhibited the growth of 
Raji cells but like galloflavin did not significantly affect cellular ATP levels. 
However at its IC50 dose highly reduced NAD levels, decreased MYC protein 
levels, and suppressed SIRT1 activity. Therefore, these observations strongly 
suggested that the effects of galloflavin observed in Raji cells could be attributed 
to  LDH inhibition. 
There is a lot of literature suggesting that SIRT1 and MYC could be considered 
attractive targets for therapeutic purposes (Milner J, 2009; Jang KY et al, 2008; 
Menssen A et al, 2012; Hermeking H, 2003). Therefore the results from our study 
not only further characterize the biological functions of the LDH enzyme, but also 
suggest that LDH inhibition may be useful as a treatment for cancer. 
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Galloflavin prevents the binding of lactate dehydrogenase A to 
single stranded DNA and inhibits RNA synthesis in cultured cells 
 
Besides its widely known role in cell energy metabolism, lactate dehydrogenase A 
(LDH-A) also displays an additional function in nuclei. Some years ago several 
authors observed that the LDH-A binds to single-stranded DNA (ssDNA) (Patel 
GL and Thompson PE, 1980; Williams KR et al, 1985; Calissano P et al, 1985; 
Grosse F et al, 1986; Sharief FS et al, 1986; Kaiserman HB et al, 1989). In 
analogy with what observed for other ssDNA-binding proteins (ssBPs) (Shamoo 
Y, 2002) an involvement of the enzyme in DNA transcription and/or replication 
was suggested; thus targeting ssBPs to prevent their interaction with ssDNA is a 
new strategy for drug development towards better cancer treatment (Zou Y et al, 
2006; Anciano Granadillo VJ et al, 2010). 
LDH-A binding to ssDNA is prevented in vitro by NADH (Calissano P et al 1985, 
Patel GL et al, 1984), suggesting that the coenzyme site is involved in the 
interaction LDH-A/ssDNA. In this paper we investigated whether galloflavin, a 
recently identified small molecule which inhibits the enzymatic activity of LDH-
A by occupying the NADH site (Manerba M et al, 2012), also hinders the 
interaction of the enzyme with ssDNA. 
Using a filter binding assay we observed that 4 μM of galloflavin inhibited the 
binding of human LDH-A to a single stranded [3H]DNA sample by 50%. After 
only 0.5–1 h, 50–100 μM galloflavin inhibited RNA synthesis in SW620 
colorectal cancer cells maintained in a medium in which galactose substituted 
General discussion 
 
 118 
glucose. In these culture conditions, SW620 cells did not produce lactic acid and 
effects caused by the inhibition of the enzymatic activity of LDH-A could be 
excluded. Therefore, the anticancer activity exerted by galloflavin on normally 
glycolysing neoplastic cells (Farabegoli F et al, 2012; Manerba M et al, 2012) was 
likely caused not only by the block of aerobic glycolysis, but also by an inhibition 
of RNA synthesis, independent from the effect on glycolysis. 
Small molecules interfering with the enzymatic activity of LDH-A are now 
searched to selectively block aerobic glycolysis for an approach to antineoplastic 
chemotherapy proposed several years ago (Fiume L, 1960; Papacostantinou J and 
Colowick SP, 1961a) and at present actively pursued (Granchi C et al, 2010; 
Ward RA et al, 2012). Our data indicate that inhibitors which occupy the NADH 
site of the enzyme besides blocking aerobic glycolysis might also prevent LDH-
A/ssDNA interaction and hamper transcription. Finally, the present results suggest 
that galloflavin, by hindering the binding of LDH-A to ssDNA, can be a tool to 
study the biological role of this interaction into the cells. 
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In recent years a growing number of studies were addressed at interfering with the 
metabolic pathways which generate energy in neoplastic cells. It has long been 
known that, to meet their energy demand, cancer cells largely rely on aerobic 
glycolysis (Warburg O, 1930). This process can be hindered by blocking lactate 
dehydrogenase (LDH), which causes a failing in the regeneration of NAD, 
reduced during the conversion of glyceraldehyde 3-phosphate to 1,3-
diphosphoglycerate, and necessary to maintain the glycolytic flow. As stated 
before, at difference from other glycolytic enzymes, LDH is probably unessential 
for normal tissues in conditions of normal functional activity and sufficient 
oxygen supply. Moreover, support for the possibility that LDH activity is not 
necessary for normal cells also comes from the findings that humans with a 
hereditary deficiency in the activity of LDH-A (the isoform of the muscle and 
liver) do not display any symptoms under normal circumstances (Kanno T et al, 
1988), and also that a complete hereditary deficiency in LDH-B (the isoform of 
the heart) is usually asymptomatic (Okumura N et al, 1999). Therefore, in the 
field of the metabolic inhibitors, LDH is considered one of the most promising 
therapeutic targets. An important result obtained from our preliminar  experiments 
was the finding that oxamic acid, an LDH inhibitor, hindered the replication of 
cells from human hepatocellular carcinomas (HCCs) by selectively blocking 
aerobic glycolysis, thus  without interfering with glucose metabolism in normal 
cells which do not rely on aerobic glycolysis. These data led us to suppose that the 
selective depletion of ATP levels in neoplastic cells could be a good strategy to 
increase the chemotherapeutic index of associated anticancer agents, like the 
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multitargeted kinase inhibitor molecules, which exert their action by binding to 
the ATP site on the targeted kinases. An interesting result, in fact, was the striking 
increase of the antiproliferative effect of sorafenib, a multitargeted kinase 
inhibitor used for the HCCs chemotherapy, in association with a LDH inhibitor 
like oxamic acid. Our results showed that the combination of the two drugs caused 
a strong depletion of ATP levels in cultured cells, which caused a rapid induction 
of cell death. This so marked decrease of ATP levels was also due to the sorafenib 
interference with oxidative phosphorylation, which made cells more dependent on 
aerobic glycolysis. As just mentioned before, oxamic acid inhibits the aerobic 
glycolysis in cells cultured in vitro only at high concentrations which are not 
expected to be reached in vivo. Nevertheless our preliminary works encouraged us 
to search for LDH inhibitors more powerful than oxamic acid and also active in 
vivo; thus we identified a new molecule, galloflavin, able to inhibits both A and B 
isoforms of LDH enzyme. We described its effects on PLC/PRF/5 cells from 
HCC in which it hindered cellular metabolism by depleting lactic acid and ATP 
production, thus leading cells to death. Galloflavin was also tested on breast 
cancer cell lines with different metabolic phenotypes, causing in these cells 
different antiproliferative mechanisms responsible for apoptosis induction. The 
most promising results were obtained in Burkitt’s lymphoma cells characterized 
by  myc overexpression  which in turn up-regulates LDH-A levels: in fact, among 
all the studied cellular models, these cells were found to be the most susceptible to 
galloflavin effect (IC50 ~ 30 μM). However, an unexpected result was to point 
out. In spite of the higher LDH-A levels, these cells did not present a much higher 
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glycolysis dependence, indeed they maintained an adequate mitochondrial 
function which provided for ATP supply. LDH inhibition in these cells did not 
produce a significant decrease  of ATP levels, but it caused an alteration in the 
balance NAD/NADH leading to the inhibition of Sirt-1 activity, which was found 
to down-regulate Myc expression, thus depriving the cells of their most important 
survival factor; interestingly, our data suggest that LDH functions to sustain 
cellular levels of NAD in addition to its role in regulating energy supplies within 
the cell. 
Finally,  we also showed that galloflavin hindered RNA synthesis by preventing 
LDH-A/single stranded DNA (ssDNA) interaction, thus exerting its anticancer 
activity not only by the block of aerobic glycolysis, but also by inhibition of RNA 
synthesis, independent from the effect on glycolysis. As discussed before, LDH-A 
seems to be implicated in the transcription of histone 2B gene (Dai RP et al, 2008) 
and its involvement in regulating the transcription of other genes cannot be 
excluded; in this way galloflavin could be a useful tool to study the biological role 
of LDH-A binding to ssDNA. 
At present, the only small molecule inhibitor tested on cultured cancer cells 
representative of human tumors with different metabolic states and/or 
pathological subtypes is galloflavin (Farabegoli F et al, 2012; Vettraino M et al, 
2013). However, this compound is active at quite high doses, when compared to 
conventionally used chemotherapeutics; moreover, it shows solubility problems 
hindering its administration in vivo. 
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To make possible a more exhaustive evaluation of the real therapeutic potential of 
LDH inhibition, critical issues are still to be solved. A first crucial point is the 
generation of more bioavailable inhibitors. LDH proved to be a very difficult 
target for medicinal chemistry researches; the identification of new inhibitors is 
made difficult by the characteristics of the enzyme active site, which is poorly 
accessible and highly polar. Furthermore, permeability through cell membranes is 
frequently hampered by excessive polarity or explicit negative changes present in 
the inhibitors, which then compromise their activity in cell-based assays and in 
vivo. Moreover, the LDH cofactor is shared by a large number of cellular 
enzymes, which are expected to display high structural homology in their NADH 
binding site. As a consequence, potential inhibitors hindering NADH binding are 
at high risk of reduced specificity.  
The availability of molecules showing good inhibitory power on cultured cells 
will also allow studies aimed at identifying the molecular alterations predictive of 
a good response of neoplastic cells to LDH inhibition. Consistently with the 
observation of Myc-induced LDH-A expression, experiments already performed 
with galloflavin have shown that neoplastic cells originating as a consequence of 
Myc over-activation are highly responsive to LDH inhibition (Vettraino M et al, 
2013). This result suggests that these tumor forms could be appropriate clinical 
conditions to test the validity of the LDH-targeted therapeutic approach. 
However, the metabolic features of cancer cells are under the control of several 
oncogenic signals, among which a major role is played by p53, Akt, PI3K and 
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Ras. Further study is needed to understand the effects of LDH inhibition on 
tumors critically depending for their growth on these specific alterations. 
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